MSD’s Needle-Free Intradermal Swine Mycoplasma Pneumonia Vaccine Approved in China
- Merck Animal Health announced on July 20, 2026, that its needle-free intradermal immunization vaccine for porcine mycoplasma pneumonia, marketed as Baozhu Lizhileda, has received regulatory approval in China.
- The approval of Baozhu Lizhileda marks a specific expansion of Merck's animal health portfolio within the Chinese market.
- The vaccine is formulated with 11 different strains to provide a broader immune response against the pneumonia-causing agents in pigs.
Merck Animal Health announced on July 20, 2026, that its needle-free intradermal immunization vaccine for porcine mycoplasma pneumonia, marketed as Baozhu Lizhileda, has received regulatory approval in China. The inactivated vaccine utilizes 11 strains to target the pneumonia virus in swine, according to reports from East Money.
Merck Animal Health Regulatory Approval in China
The approval of Baozhu Lizhileda marks a specific expansion of Merck’s animal health portfolio within the Chinese market. According to the announcement released on July 20, 2026, the vaccine is designed as an inactivated product specifically targeting porcine mycoplasma pneumonia. The product employs a needle-free intradermal delivery system, which differs from traditional subcutaneous or intramuscular injection methods.
The vaccine is formulated with 11 different strains to provide a broader immune response against the pneumonia-causing agents in pigs. This regulatory milestone allows Merck to distribute the immunization technology to commercial swine operations across China, according to data sourced from East Money.
Technical Specifications of Baozhu Lizhileda
The core of the approval centers on the vaccine’s delivery mechanism and its composition. Based on the company’s announcement, the product is characterized by three primary technical features:
- Needle-Free Delivery: The vaccine uses an intradermal immunization method that eliminates the need for traditional needles.
- Inactivated Formulation: The vaccine is an inactivated type, meaning it uses killed versions of the virus to trigger an immune response without causing the disease.
- Multi-Strain Coverage: The formulation includes 11 specific strains to address the variability of porcine mycoplasma pneumonia.
By utilizing intradermal delivery, the vaccine targets the immune-rich layer of the skin, which is often cited in veterinary medicine as a way to enhance the efficacy of the immune response compared to deeper muscle injections.